lixisenatide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| peptides and glycopeptides | 4815 | 320367-13-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic GLUCAGON-LIKE PEPTIDE-1 RECEPTOR (GLP-1) agonist that binds GLP-1 receptor that is used to control blood sugar levels in patients with TYPE 2 DIABETES; amino acid sequence is H-HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSK KKKKK-NH2 (ZP10A).
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 40 | U | P |
| 20 | mcg | P |
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 24, 2013 | PMDA | Sanofi K.K. | |
| July 27, 2016 | FDA | SANOFI-AVENTIS US LLC | |
| Feb. 1, 2013 | EMA | Sanofi-Aventis Groupe |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Diabetic ketoacidosis | 54.53 | 51.51 | 13 | 163 | 34109 | 79710103 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A10AE54 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES INSULINS AND ANALOGUES Insulins and analogues for injection, long-acting |
| ATC | A10BJ03 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues |
| FDA CS | M0160181 | Glucagon-Like Peptide 1 |
| FDA MoA | N0000020058 | Glucagon-like Peptide-1 (GLP-1) Agonists |
| FDA EPC | N0000178480 | GLP-1 Receptor Agonist |
| CHEBI has role | CHEBI:35526 | antidiabetic |
| CHEBI has role | CHEBI:63726 | neuroprotective agents |
| CHEBI has role | CHEBI:71196 | GLP-1 receptor agonist |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.15 | acidic |
| pKa2 | 3.62 | acidic |
| pKa3 | 3.86 | acidic |
| pKa4 | 4.07 | acidic |
| pKa5 | 4.31 | acidic |
| pKa6 | 4.6 | acidic |
| pKa7 | 12.21 | acidic |
| pKa8 | 12.44 | acidic |
| pKa9 | 12.46 | acidic |
| pKa10 | 12.61 | acidic |
| pKa11 | 12.8 | acidic |
| pKa12 | 12.94 | acidic |
| pKa13 | 13.0 | acidic |
| pKa14 | 13.01 | acidic |
| pKa15 | 13.16 | acidic |
| pKa16 | 13.28 | acidic |
| pKa17 | 13.31 | acidic |
| pKa18 | 13.37 | acidic |
| pKa19 | 13.43 | acidic |
| pKa20 | 13.45 | acidic |
| pKa21 | 13.6 | acidic |
| pKa22 | 13.66 | acidic |
| pKa23 | 13.67 | acidic |
| pKa24 | 13.79 | acidic |
| pKa25 | 13.81 | acidic |
| pKa26 | 13.82 | acidic |
| pKa27 | 13.96 | acidic |
| pKa28 | 13.98 | acidic |
| pKa29 | 11.5 | Basic |
| pKa30 | 11.39 | Basic |
| pKa31 | 11.16 | Basic |
| pKa32 | 10.98 | Basic |
| pKa33 | 10.81 | Basic |
| pKa34 | 10.64 | Basic |
| pKa35 | 10.45 | Basic |
| pKa36 | 10.23 | Basic |
| pKa37 | 9.85 | Basic |
| pKa38 | 7.86 | Basic |
| pKa39 | 5.98 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Glucagon-like peptide 1 receptor | GPCR | AGONIST | IC50 | 8.85 | SCIENTIFIC LITERATURE | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D09729 | KEGG_DRUG |
| 4036289 | VANDF |
| CHEBI:85662 | CHEBI |
| CHEMBL2108336 | ChEMBL_ID |
| C479460 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7387 | IUPHAR_LIGAND_ID |
| 8970 | INN_ID |
| DB09265 | DRUGBANK_ID |
| 74O62BB01U | UNII |
| 1440051 | RXNORM |
| 244072 | MMSL |
| 29296 | MMSL |
| d08068 | MMSL |
| 015267 | NDDF |
| 708808004 | SNOMEDCT_US |
| 763570007 | SNOMEDCT_US |
| C2973895 | UMLSCUI |
| 90472060 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ADLYXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0024-5747 | INJECTION, SOLUTION | 100 ug | SUBCUTANEOUS | BLA | 33 sections |
| ADLYXIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0024-5747 | INJECTION, SOLUTION | 100 ug | SUBCUTANEOUS | BLA | 33 sections |
| Soliqua 100/33 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0024-5761 | INJECTION, SOLUTION | 33 ug | SUBCUTANEOUS | BLA | 33 sections |
| Soliqua 100/33 | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0024-5761 | INJECTION, SOLUTION | 33 ug | SUBCUTANEOUS | BLA | 33 sections |